CAJ | 학술논문

目的观察依西美坦治疗绝经后乳腺癌骨转移的疗效和副作用.方法 110例绝经后乳腺癌骨转移患者给予依西美坦25 mg,每日1次,连服至少8周.结果 110例可评价疗效和毒副作用患者中,完全缓解(CR)7列,部分缓解(PR)28例,总有效率31.8％；稳定(SD)≥24周者39例.临床获益患者(CR +PR+ SD)≥24周者74例,占67.3％,病情进展(PD)12例,占10.9％.激素受体(ER,PR)阳性者获益机会较多；既往治疗、乳腺癌病理类型、骨转移及是否合并肝、肺、淋巴结转移与疗效无关(x2值分别为0.045、0.078、0.200,P均＞0.05).治疗中无严重不良反应.结论依西美坦治疗绝经后乳腺癌骨转移有一定疗效,药物副反应轻微,患者耐受性良好.
목적 관찰의서미탄치료절경후유선암골전이적료효화부작용.방법 110례절경후유선암골전이환자급여의서미탄25 mg,매일1차,련복지소8주.결과 110례가평개료효화독부작용환자중,완전완해(CR)7렬,부분완해(PR)28례,총유효솔31.8％；은정(SD)≥24주자39례.림상획익환자(CR +PR+ SD)≥24주자74례,점67.3％,병정진전(PD)12례,점10.9％.격소수체(ER,PR)양성자획익궤회교다；기왕치료、유선암병리류형、골전이급시부합병간、폐、림파결전이여료효무관(x2치분별위0.045、0.078、0.200,P균＞0.05).치료중무엄중불량반응.결론 의서미탄치료절경후유선암골전이유일정료효,약물부반응경미,환자내수성량호.
Objective To observe the efficacy and side effects of exemestane in postmenopausal breast cancer patients with bone metastasis.Methods One hundred and ten postmenopausal breast cancer patients with bone metastasis were treated with exemestane 25 mg.Results In the evaluable data from 110 patients,the complete remission(CR)was encountered in 7 cases,partial remission(PR)in 28 cases,with a total response rate of 31.8％ ;Thirty nine patients had stabled diseases for more than 24 weeks.It produced a clinical benefit (CR + PR + SD)over 24 weeks in 74 cases(67.3％).Diseases progressed in 12 of the cases(10.9％).The patients with positive ER and PR status had a higher chance to be benefited from the treatment than those with negative receptor status.The clinical efficacy was not correlated with treatment history,pathological subtypes and bone,liver,lung and lymph node metastasis(x2 =0.045,0.078,0.200,P ＞ 0.05).No severe adverse effects were observed.Conclusion Exemestane is effective to treat bone metastasis of breast cancer with minor adverse reactions and good tolerability.